Edesa Biotech Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 18

Employees

  • Stock Symbol
  • EDSA

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.05
  • (As of Tuesday Closing)

Edesa Biotech General Information

Description

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Contact Information

Website
www.edesabiotech.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 100 Spy Court
  • Markham, Ontario L3R 5H6
  • Canada
+1 (289)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Life Sciences
Corporate Office
  • 100 Spy Court
  • Markham, Ontario L3R 5H6
  • Canada
+1 (289)

Edesa Biotech Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Edesa Biotech Stock Performance

As of 08-Jul-2025, Edesa Biotech’s stock price is $2.05. Its current market cap is $14.4M with 7.02M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.05 $2.06 $1.55 - $5.59 $14.4M 7.02M 19.6K -$1.55

Edesa Biotech Financials Summary

As of 31-Mar-2025, Edesa Biotech has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 31-Mar-2025 FY 2024 30-Sep-2024 FY 2023 30-Sep-2023 FY 2022 30-Sep-2022
EV 16,480 12,449 6,989 1,477
Revenue 0 0 0 0
EBITDA (5,725) (6,137) (8,480) (17,493)
Net Income (5,838) (6,170) (8,374) (17,549)
Total Assets 16,454 3,814 8,890 11,576
Total Debt 0 20 94 19
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Edesa Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Edesa Biotech‘s full profile, request access.

Request a free trial

Edesa Biotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in expl
Drug Discovery
Markham, Canada
18 As of 2025

Cranford, NJ
 

Stockholm, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Edesa Biotech Competitors (6)

One of Edesa Biotech’s 6 competitors is Citius Pharma, a Formerly Angel backed company based in Cranford, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Citius Pharma Formerly Angel backed Cranford, NJ
Vicore Pharma Holding Formerly VC-backed Stockholm, Sweden
Eli Lilly Corporation Indianapolis, IN
Cipla Corporation Mumbai, India
Aclaris Therapeutics Formerly VC-backed Wayne, PA
To view Edesa Biotech’s complete competitors history, request access »

Edesa Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Edesa Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Edesa Biotech‘s full profile, request access.

Request a free trial

Edesa Biotech Acquisitions (1)

Edesa Biotech’s most recent deal was a Merger/Acquisition with Stellar Biotechnologies for . The deal was made on 07-Jun-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Stellar Biotechnologies 07-Jun-2019 Merger/Acquisition Biotechnology
To view Edesa Biotech’s complete acquisitions history, request access »

Edesa Biotech FAQs

  • When was Edesa Biotech founded?

    Edesa Biotech was founded in 2015.

  • Where is Edesa Biotech headquartered?

    Edesa Biotech is headquartered in Markham, Canada.

  • What is the size of Edesa Biotech?

    Edesa Biotech has 18 total employees.

  • What industry is Edesa Biotech in?

    Edesa Biotech’s primary industry is Drug Discovery.

  • Is Edesa Biotech a private or public company?

    Edesa Biotech is a Public company.

  • What is Edesa Biotech’s stock symbol?

    The ticker symbol for Edesa Biotech is EDSA.

  • What is the current stock price of Edesa Biotech?

    As of 08-Jul-2025 the stock price of Edesa Biotech is $2.05.

  • What is the current market cap of Edesa Biotech?

    The current market capitalization of Edesa Biotech is $14.4M.

  • Who are Edesa Biotech’s competitors?

    Citius Pharma, Vicore Pharma Holding, Eli Lilly, Cipla, and Aclaris Therapeutics are some of the 6 competitors of Edesa Biotech.

  • What is Edesa Biotech’s annual earnings per share (EPS)?

    Edesa Biotech’s EPS for 12 months was -$1.55.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »